Navigation Links
NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
Date:10/21/2009

SOUTH SAN FRANCISCO, Calif., Oct. 21 /PRNewswire/ -- NGM Biopharmaceuticals, Inc. (NGM), a private company dedicated to the discovery and development of novel biotherapeutics for the treatment of Type 2 diabetes and other metabolic diseases, today announced that Arthur D. Levinson, Ph.D., the Chairman of Genentech's Board of Directors, has been appointed to NGM's Board of Directors. Under Dr. Levinson's leadership as Chairman and Chief Executive Officer from 1995 to 2009, Genentech became a leading global therapeutics company that was widely recognized as the most innovative biotechnology company in the industry.

Founded in 2008, NGM has created a proprietary discovery platform and pipeline based on biological insights into the relationship between bariatric gastric bypass surgery and post-surgical resolution of Type 2 diabetes and other metabolic disorders. Dr. Levinson will join other distinguished advisors in guiding the Company's research, development and business strategies.

"NGM has the attributes and values that I believe are fundamental to building an innovative and sustainable biotechnology company," said Dr. Levinson. "The company's creative approach to scientific research should provide new insights into disease processes, and support the discovery of differentiated, clinically important medicines."

"Art's accomplishments and leadership during his thirty years at Genentech are legendary," said David V. Goeddel, Ph.D., NGM's Chairman and Chief Executive Officer. "His scientific and business acumen will be invaluable in shaping NGM's continued progress."

Dr. Levinson is currently the chairman of Genentech's Board of Directors, an advisor to Genentech's Research and Early Development center and a member of Roche's Scientific Resource Board. In addition, he will be nominated to the Board of Directors of Roche Holding Ltd. in March 2010. Among his significant commitments are his memberships on the Bo
'/>"/>

SOURCE NGM Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
2. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
3. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
4. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
5. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
7. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
8. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
9. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... Sanomedics, Inc. (OTC: SIMH) an international medical technology company ... growing behavioral health sector with the strategic acquisition of ... as a Services (SaaS) provider, specialized in Electronic Health ... centers. "The strategic acquisition of Zen ... health sector where the number of treatment service and ...
(Date:5/26/2015)... , May 26, 2015  MGC Diagnostics Corporation (NasdaqCM: MGCD), ... to discuss its financial results for the second quarter of ... at 4:30 p.m. ET on Tuesday, June 2, 2015. The ... fiscal 2015 at the close of the markets on Tuesday, ... 317-6789 or (412) 317-6789 to access the conference call, or ...
(Date:5/26/2015)... 2015 Boehringer Ingelheim today announced that ... once-daily STIOLTO™ RESPIMAT ® (tiotropium bromide and ... a long-term, once-daily maintenance treatment of airflow obstruction ... including chronic bronchitis and/or emphysema. STIOLTO RESPIMAT is ... of COPD. COPD, which includes chronic ...
Breaking Medicine Technology:Sanomedics Targeting Behavioral Health and Electronic Health Records with Strategic Acquisition of Zen Charts 2Sanomedics Targeting Behavioral Health and Electronic Health Records with Strategic Acquisition of Zen Charts 3MGC Diagnostics Corporation to Report Second Quarter Fiscal 2015 Financial Results on Tuesday, June 2, 2015 2FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 2FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 3FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 4FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 5FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 6FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 7FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 8FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 9FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 10FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 11FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 12FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 13
... 2012  Vitamin Shoppe, Inc. (NYSE: VSI ), ... products, today announced that it will be participating at ... Retail Conference taking place March 7 - 8, 2012 ... be Mike Archbold, President and COO and Brenda Galgano, ...
... Feb. 29, 2012 Talyst , a leader in ... annual 340B Coalition Winter Conference. The new tool allows health ... The 340B Savings Calculator lets health systems predict their ... "Talyst is dedicated to ensure you receive ...
Cached Medicine Technology:Vitamin Shoppe, Inc. Announces Participation at Investor Conference 2
(Date:5/26/2015)... 26, 2015 The American College of Traditional ... for the Open House/Free Application Day on Wednesday, July 22. ... 4 p.m. and will be held at ACTCM Pioneer Square, ... After checking in, attendees will be greeted with an introduction ... of the campus at 11:45 a.m. Lunch will be served ...
(Date:5/26/2015)... May 26, 2015 Abington is ... Wellness, a physician practice with seven medical professionals, ... the eighth primary-care site in the United States ... medical home by the National Committee for Quality ... primary, preventative and sick care – including routine ...
(Date:5/26/2015)... 26, 2015 It was an evening ... in Colorado. On Wednesday, May 13, The Denver Foundation ... new era of community-based giving with its Annual Celebration, ... in the Making,” the event celebrated the donors, leaders, ... to mobilize resources for good. , “If your organization, ...
(Date:5/26/2015)... Allprovide, the all-natural raw pet food company, today ... now available in three Georgia stores: Pooch-n-Paws in Suwannee; ... Dog Company in Kennesaw. , Allprovide is based out ... climate controlled facility. The fresh ingredients come from select ... food is triple-tested for quality. Unlike most pet foods, ...
(Date:5/26/2015)... Downers Grove, IL (PRWEB) May 26, 2015 ... Worker who is an expert in Neuro-Linguistic Programming, or ... a Master Practitioner in Rapid Resolution Therapy® or RRT®. ... the field of NLP and applied it to specific ... NLP to psychological treatment for over 20 years. ...
Breaking Medicine News(10 mins):Health News:ACTCM to Host Summer Open House 2Health News:Family Medicine, Geriatrics and Wellness Joins Abington Health Physicians 2Health News:Celebrating "Our Future in the Making" 2Health News:Celebrating "Our Future in the Making" 3Health News:Allprovide, the All-Natural Pet Food, Available At Georgia Retailers 2
... initiatives to encourage healthy eating habits, teens in middle ... 1999, a new study reveals.// And the situation only ... vegetable intake is important for the prevention of future ... Larson, M.P.H. “So it’s important to know whether intakes ...
... recent study by a Saint Louis University researcher confirms findings ... of a gene that causes them to metabolize food// differently, ... ,Edward Weiss, Ph.D., assistant professor of nutrition and dietetics ... looked at a relatively common version of a gene called ...
... by biochemists at the University of California, San Diego ... which inflammation can promote cancer. The findings// may provide ... ,The study shows that what scientists thought were two ... cells’ response to dangers such as invading organisms—are actually ...
... has shown conclusively that a neuropeptide, melanin concentrating hormone ... role in// increasing appetite in people, plays a role ... secretion of insulin. This finding has the potential to ... stimulate the production of insulin-producing beta cells in the ...
... simple scoring system for use by physicians predicts early risk ... known as TIA and also called// a "mini-stroke," according to ... every year in the United States and about 70,000 in ... by temporary reduction in blood and oxygen supply to part ...
... range from the very serious Fetal Alcohol Syndrome to ... Disorders. The timing of alcohol consumption, its frequency, the ... elements of identifying risk. A new survey has found ... consumed alcohol during the three months before pregnancy; nearly ...
Cached Medicine News:Health News:Today’s Teens Slacking on Fruit, Veggie Intak 2Health News:Molecular Link Between Inflammation and Cancer Discovered 2Health News:Molecular Link Between Inflammation and Cancer Discovered 3Health News:Role of Appetite Hormone MCH in Insulin Production Revealed 2Health News:New Tool Improves Prediction of Stroke Risk 2Health News:Risk Factors of Drinking Before, and During, Pregnancy 2
... In 2000, Applied Biosystems introduced ... I S M 3100 Genetic Analyzer.,Now ... instrument is available in our new ... for low- to-medium-throughput laboratory needs, the ...
... Quality Analysis System) developed by Pablo Artal, ... first diagnostic tool for ophthalmology that provides ... system. Never before has an ophthalmologist had ... quality of vision. , ,OQAS works by ...
... kit uses proteins produced with recombinant technology, that ... which are capable of detecting the different types ... are proteins with amino acid sequences repeated in ... the acute phase of the infection, it reacts ...
Elisa test for qualitative detection of Total antibodies to Trypanosoma Cruzi in human serum or plasma....
Medicine Products: